CompletedNot Applicable

Memory and Attention Adaptation Training-Geriatrics (MAAT-G)

United States4 participantsStarted 2020-06-12

Plain-language summary

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and test usability of the intervention.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have a diagnosis of invasive breast cancer
✓. Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cycles remaining.
✓. Be age 65 or older
✓. Able to provide informed consent
✓. Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)

Exclusion criteria

✕. Have surgery planned within 3 months of consent
✕. Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
✕. Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible.

What they're measuring

System Usability Scale (SUS)

Timeframe: Post-Intervention (up to 2 weeks)

Experience Interview

Timeframe: Post-Intervention (up to 2 weeks)

Trial details

NCT IDNCT04230941

SponsorUniversity of Rochester

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-01

Results submitted2022-12-20

View on ClinicalTrials.gov More Cancer-related Problem/Condition trials